

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
Comerica Bank, a Texas Banking Association and Authorized Foreign Bank Under the Bank Act (Canada)	02/27/2013
RECEIVING PARTY DATA	
Name:	Proventiv Therapeutics , LLC
Street Address:	2333 Waukegan Road
Internal Address:	Suite E100
City:	Bannockburn
State/Country:	ILLINOIS
Postal Code:	60015
PROPERTY NUMBERS Total: 8	
Property Type	Number
Application Number:	11549001
Patent Number:	8361488
Application Number:	12278053
Patent Number:	8329677
Application Number:	12597224
Application Number:	12597234
Application Number:	12935139
Patent Number:	8207149
CORRESPONDENCE DATA	
Fax Number:	3124740448
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	anagelberg@marshallip.com
Correspondent Name:	Marshall, Gerstein & Borun LLP
Address Line 1:	233 South Wacker Drive

OP \$320.00 11549001

Address Line 2: Suite 6300
Address Line 4: Chicago, ILLINOIS 60606

ATTORNEY DOCKET NUMBER: 31138/10049

NAME OF SUBMITTER: Audrey Nagelberg

Total Attachments: 9
source=Proventiv_release#page1.tif
source=Proventiv_release#page2.tif
source=Proventiv_release#page3.tif
source=Proventiv_release#page4.tif
source=Proventiv_release#page5.tif
source=Proventiv_release#page6.tif
source=Proventiv_release#page7.tif
source=Proventiv_release#page8.tif
source=Proventiv_release#page9.tif

RELEASE OF SECURITY INTEREST

WHEREAS, **Proventiv Therapeutics, LLC** ("Proventiv"), a Delaware corporation with offices at Corporation Trust Centre 1209 Orange Street, Wilmington, Delaware is the owner of the patents set forth in Exhibit 1 (collectively, the "Patents");

WHEREAS, **Comerica Bank**, a Texas banking association with offices at Suite 2210, South Tower, Royal Bank Plaza, PO Box 61, Toronto, Ontario, M5J 2J2 entered into a Intellectual Property Security Agreement with Proventiv dated July 31, 2012 (the "Intellectual Property Security Agreement") by which Proventiv granted to Comerica Bank a lien and security interest as set forth in the Intellectual Property Security Agreement (the "Security Interest") in the Patents and other Collateral (as defined in the Intellectual Property Security Agreement);

WHEREAS a Notice of Security Interest was filed against the Canadian Patents with the Canadian Intellectual Property Office on August 30, 2012 and against the USA Patents with the United States Patent and Trademark Office on August 16, 2012;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:


1. Comerica Bank hereby releases and discharges its Security Interest in the Collateral (as defined in the Intellectual Property Security Agreement).
2. To the extent Comerica retains any such interest, Comerica hereby assigns, transfers and conveys to Proventiv all of Comerica's rights, title and interest, now owned or hereinafter acquired, that it may have whether by assignment or otherwise, in and to any mortgage and continuing security interest and collateral assignment in the Collateral (as defined in the Intellectual Property Security Agreement). Such assignment, transfer and conveyance by Comerica is made without any representation or warranty (express or implied) by Comerica.
3. Comerica hereby agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions as may be reasonably requested or are required in order to more fully and effectively carry out the purposes of this Release of Security Interest, all at the expense of Proventiv.

4. This Assignment shall be binding upon and enure to the benefit of the respective successors and assigns of the parties hereto.

IN WITNESS WHEREOF, the undersigned have caused their duly authorized representatives to execute this Release of Security Interest effective as of the date shown above and in the capacities shown below.

Dated: February, 27, 2013

PROVENTIV THERAPEUTICS, LLC

By: 
Name: Charles Bishop
Title: President & CEO

COMERICA BANK

By: _____
Name:
Title:

Release of IP Security - Proventiv Therapeutics, LLC

IN WITNESS WHEREOF, the undersigned have caused their duly authorized representatives to execute this Release of Security Interest effective as of the date shown above and in the capacities shown below.

Dated: February, 27, 2013

PROVENTIV THERAPEUTICS, LLC

By: _____
Name: Charles Bishop
Title: President & CEO

COMERICA BANK

By:  _____
Name: Bryce Alkman
Title: Vice-President

EXHIBIT 1

Patents

U.S.

Title	App. No.	Filing Date	Reg. No.	Date Granted
Methods compositions, uses, and kits useful for vitamin D deficiency and related disorders	12/935139	4/2/09	n/a	n/a
Methods and compounds for vitamin D therapy	12/597224	4/25/08	n/a	n/a
Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease	12/597234	4/25/08	n/a	n/a
Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency	11/549001	10/12/06	n/a	n/a
Methods and Compositions for Controlled Release oral Dosage of a Vitamin D Compound	n/a	n/a	8,207,149	June 26, 2012
Treating Vitamin D Insufficiency and Deficiency with 25-Hydroxyvitamin D ₂ and 25-Hydroxyvitamin D ₃	12/278,053	2/23/09	n/a	n/a
Method of Treating and Preventing Secondary Hyperparathyroidism	12/305,572	3/2/09	n/a	n/a
Methods and Compositions for Reducing Parathyroid Levels	PCT/US11/30404	March 29, 2011	n/a	n/a
Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	12/109,983	April 25, 2008	n/a	n/a

Non-U.S.:

Jurisdiction	Title	App. No.	Filing Date	Reg. No.	Date Granted
--------------	-------	----------	-------------	----------	--------------

Canada	Methods and Articles for Treating 25-Hydroxyvitamin D Insufficiency and Deficiency	2,624,897	October 12, 2006	n/a	n/a
Europe	Methods and Articles for Treating 25-Hydroxyvitamin D Insufficiency and Deficiency	06836270.6	October 12, 2006	n/a	n/a
Japan	Methods and Articles for Treating 25-Hydroxyvitamin D Insufficiency and Deficiency	2008-535659	October 12, 2006	n/a	n/a
Canada	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	2,683,997	April 25, 2008	n/a	n/a
China	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	200880013357.6	April 25, 2008	n/a	n/a
Europe	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	08746908.6	April 25, 2008	n/a	n/a
Europe	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	12154573.5	April 25, 2008	n/a	n/a
Hong Kong	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	10108648.7	April 25, 2008	n/a	n/a
Japan	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	2010-506520	April 25, 2008	n/a	n/a
South Korea	Methods and Compositions for Controlled Release Oral Dosage of a Vitamin D Compound	10-2009-7024328	April 25, 2008	n/a	n/a
Canada	Treating Vitamin D Insufficiency and Deficiency with 25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3	2,640,094	February 2, 2007	n/a	n/a

Europe	Treating Vitamin D Insufficiency and Deficiency with 25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3	07763210.7	February 2, 2007	n/a	n/a
Japan	Treating Vitamin D Insufficiency and Deficiency with 25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3	2008-553520	February 2, 2007	n/a	n/a
Canada	Method and Compounds for Vitamin D Therapy	2,684,778	April 25, 2008	n/a	n/a
Europe	Method and Compounds for Vitamin D Therapy	08746915.1	April 25, 2008	n/a	n/a
Japan	Method and Compounds for Vitamin D Therapy	2010-506521	April 25, 2008	n/a	n/a
Canada	Method of Treating and Preventing Secondary Hyperparathyroidism	2,655,499	June 21, 2007	n/a	n/a
Europe	Method of Treating and Preventing Secondary Hyperparathyroidism	07840277.3	June 21, 2007	n/a	n/a
Japan	Method of Treating and Preventing Secondary Hyperparathyroidism	2009-516725	June 21, 2007	n/a	n/a
Canada	Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease	2,683,514	April 25, 2008	n/a	n/a
Europe	Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease	08746920.1	April 25, 2008	n/a	n/a
Japan	Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease	2010-506524	April 25, 2008	n/a	n/a
Canada	Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof	2,714,996	April 2, 2009	n/a	n/a

China	Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof	2009801204 04.1	April 2, 2009	n/a	n/a
Europe	Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof	09729007.6	April 2, 2009	n/a	n/a
Hong Kong	Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof	11111063.6	April 2, 2009	n/a	n/a
Korea	Methods of Diagnosing Vitamin D Deficiency, Susceptibility Thereto, Treatment Thereof, and Prevention Thereof	10-2010-7024664	April 2, 2009	n/a	n/a

EXHIBIT C

Trademarks

U.S.:

Mark	App. No.	Filing Date	Reg. No.	Reg. Date
CYTOCHROMA & Design	78/415,141	April 28, 2004	n/a	n/a
D-REPLA	85/392,751	August 8, 2011	n/a	n/a
REPLIDEA	85/392,298	August 8, 2011	n/a	n/a
ALIVIMO	85/392,305	August 8, 2011	n/a	n/a
EQUODI	85/392,753	August 8, 2011	n/a	n/a
RAYACAL	85/392,308	August 8, 2011	n/a	n/a

Non- U.S.:

Jurisdiction	Mark	App. No.	Filing Date	Reg. No.	Date Granted
Canada	CYTOCHROMA & design	1,215,000	April 28, 2004	n/a	n/a
Canada	D-REPLA	1559924	January 16, 2012	n/a	n/a
China	D-REPLA	10445655	January 20, 2012	n/a	n/a
EU	D-REPLA	10559052	January 13, 2012	n/a	n/a
India	D-REPLA	TBD	January 31, 2012	n/a	n/a
Japan	D-REPLA	2012-3286	January 20, 2012	n/a	n/a
Canada*	REPLIDEA	1559923	January 16, 2012	n/a	n/a
China*	REPLIDEA	10445656	January 20, 2012	n/a	n/a
EU*	REPLIDEA	10559276	January 13, 2012	n/a	n/a
India*	REPLIDEA	TBD	January 31, 2012	n/a	n/a
Japan	REPLIDEA	2012-3287	January 20, 2012	n/a	n/a

14140123.1

Release of IP Security – Proventiv Therapeutics, LLC

RECORDED: 03/04/2013

PATENT
REEL: 029914 FRAME: 0077